Exelixis Inc (EXEL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $16.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Exelixis Inc (EXEL) Earnings: Report Dates and Results
Exelixis (EXEL) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Exelixis reported EPS of $0.85, above the $0.79 estimate. It beat the EPS estimate in each of the last 10 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
EXEL has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 6.4% above the $0.94 reported for the quarter ended Dec 31, 2025.
EXEL Earnings Call
The latest EXEL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, EXEL beat 31, missed 4 and matched 4. The widest gap in the table came in the quarter ended Mar 31, 2017, when EPS landed 600.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.85 | $0.79 | N/A | +7.59% | Beat | +9.0% | 10 | 1 up, 2 down | Oct 29, 2026 | N/A |
| Jun 30, 2026 | $0.82 | $0.75 | N/A | +9.33% | Beat | +9.3% | 11 | 2 up, 0 down | Aug 5, 2026 | $628.69M |
| Mar 31, 2026 | $0.87 | $0.76 | $0.69 - $0.82 | +14.47% | Beat | +40.3% | 10 | 1 up, 2 down | May 5, 2026 | $610.81M |
| Dec 31, 2025 | $0.94 | $0.81 | $0.38 - $1.02 | +16.05% | Beat | +70.9% | 13 | 6 up, 1 down | Feb 10, 2026 | $598.66M |
| Sep 30, 2025 | $0.78 | $0.67 | $0.53 - $0.71 | +16.42% | Beat | +66.0% | 13 | 1 up, 1 down | Nov 4, 2025 | $597.75M |
| Jun 30, 2025 | $0.75 | $0.65 | $0.52 - $0.72 | +15.38% | Beat | -10.7% | 12 | 4 up, 1 down | Jul 28, 2025 | $568.26M |
| Mar 31, 2025 | $0.62 | $0.37 | $0.34 - $0.55 | +69.12% | Beat | +264.7% | 11 | 3 up, 0 down | May 13, 2025 | $555.45M |
| Dec 31, 2024 | $0.55 | $0.49 | $0.24 - $0.63 | +12.24% | Beat | +66.7% | 14 | 5 up, 2 down | Feb 11, 2025 | $566.75M |
| Sep 30, 2024 | $0.47 | $0.42 | N/A | +11.90% | Beat | +370.0% | 13 | 4 up, 1 down | Oct 29, 2024 | $539.54M |
| Jun 30, 2024 | $0.84 | $0.37 | N/A | +127.03% | Beat | +171.0% | 15 | 5 up, 1 down | Aug 6, 2024 | $637.18M |
| Mar 31, 2024 | $0.17 | $0.29 | $0.11 - $0.47 | -41.38% | Miss | +6.3% | 15 | 4 up, 1 down | Apr 30, 2024 | $425.23M |
| Dec 31, 2023 | $0.33 | $0.31 | N/A | +6.45% | Beat | N/A | 13 | 7 up, 3 down | Feb 6, 2024 | $479.65M |
| Sep 30, 2023 | $0.10 | $0.19 | -$0.13 - $0.27 | -47.37% | Miss | -67.7% | 13 | 0 up, 2 down | Nov 1, 2023 | $471.92M |
| Jun 30, 2023 | $0.31 | $0.22 | $0.09 - $0.22 | +40.91% | Beat | +10.7% | 12 | 2 up, 1 down | Aug 1, 2023 | $469.85M |
| Mar 31, 2023 | $0.16 | $0.22 | N/A | -27.27% | Miss | -38.5% | 13 | 1 up, 0 down | May 9, 2023 | $408.79M |
| Dec 31, 2022 | -$0.03 | -$0.05 | -$0.24 - $0.07 | +40.00% | Beat | -108.6% | 11 | 5 up, 0 down | Feb 7, 2023 | $423.92M |
| Sep 30, 2022 | $0.31 | $0.24 | $0.10 - $0.25 | +29.17% | Beat | +55.0% | 11 | 1 up, 3 down | Nov 1, 2022 | $411.74M |
| Jun 30, 2022 | $0.28 | $0.24 | $0.10 - $0.24 | +16.67% | Beat | -24.3% | 10 | 1 up, 3 down | Aug 9, 2022 | $419.43M |
| Mar 31, 2022 | $0.26 | $0.23 | N/A | +13.04% | Beat | +188.9% | 9 | 1 up, 0 down | May 10, 2022 | $355.98M |
| Dec 31, 2021 | $0.35 | $0.16 | -$0.04 - $0.17 | +118.75% | Beat | +150.0% | 10 | N/A | Feb 17, 2022 | $451.14M |
| Sep 30, 2021 | $0.20 | $0.27 | N/A | -25.93% | Miss | +400.0% | 10 | N/A | Nov 2, 2021 | $328.42M |
| Jun 30, 2021 | $0.37 | $0.14 | N/A | +164.29% | Beat | +48.0% | 12 | N/A | Aug 5, 2021 | $385.18M |
| Mar 31, 2021 | $0.09 | $0.09 | N/A | 0.00% | In line | -52.6% | 12 | N/A | May 6, 2021 | $270.23M |
| Dec 31, 2020 | $0.14 | $0.10 | -$0.05 - $0.12 | +40.00% | Beat | -36.4% | 11 | N/A | Feb 10, 2021 | $270.05M |
| Sep 30, 2020 | $0.04 | $0.04 | -$0.16 - $0.10 | 0.00% | In line | -88.2% | 12 | N/A | Nov 5, 2020 | $231.09M |
| Jun 30, 2020 | $0.25 | $0.14 | $0.08 - $0.18 | +78.57% | Beat | -13.8% | 12 | N/A | Aug 6, 2020 | $259.48M |
| Mar 31, 2020 | $0.19 | $0.17 | $0.03 - $0.21 | +11.76% | Beat | -20.8% | 11 | N/A | May 5, 2020 | $226.91M |
| Dec 31, 2019 | $0.22 | $0.17 | $0.10 - $0.22 | +29.41% | Beat | -40.5% | 11 | N/A | Feb 25, 2020 | $240.31M |
| Sep 30, 2019 | $0.34 | $0.22 | N/A | +54.55% | Beat | -17.1% | 9 | N/A | Oct 30, 2019 | $271.70M |
| Jun 30, 2019 | $0.29 | $0.28 | N/A | +3.57% | Beat | +3.6% | 11 | N/A | Jul 31, 2019 | $240.28M |
| Mar 31, 2019 | $0.24 | $0.24 | $0.20 - $0.30 | 0.00% | In line | -35.1% | 11 | N/A | May 1, 2019 | $215.49M |
| Dec 31, 2018 | $0.37 | $0.23 | $0.16 - $0.33 | +60.87% | Beat | +208.3% | 11 | N/A | Feb 12, 2019 | $228.60M |
| Sep 30, 2018 | $0.41 | $0.17 | $0.10 - $0.31 | +141.18% | Beat | +57.7% | 10 | N/A | Nov 1, 2018 | $225.40M |
| Jun 30, 2018 | $0.28 | $0.16 | $0.11 - $0.24 | +75.00% | Beat | +250.0% | 8 | N/A | Aug 1, 2018 | $186.11M |
| Mar 31, 2018 | $0.37 | $0.15 | $0.08 - $0.30 | +146.67% | Beat | +640.0% | 8 | N/A | May 2, 2018 | $213.72M |
| Dec 31, 2017 | $0.12 | $0.12 | $0.08 - $0.17 | 0.00% | In line | 0.0% | 10 | N/A | Feb 26, 2018 | $120.07M |
| Sep 30, 2017 | $0.26 | $0.07 | $0.05 - $0.11 | +271.43% | Beat | +2500.0% | 10 | N/A | Nov 1, 2017 | $152.51M |
| Jun 30, 2017 | $0.08 | $0.03 | $0.01 - $0.07 | +166.67% | Beat | N/A | 9 | N/A | Aug 2, 2017 | $99.01M |
| Mar 31, 2017 | $0.05 | -$0.01 | N/A | +600.00% | Beat | N/A | N/A | N/A | May 1, 2017 | $80.89M |
| Dec 31, 2016 | $0.12 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | Feb 27, 2017 | $77.58M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.09, up 52.2% from the year before. It was -$0.30 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.09 | +52.2% |
| Dec 31, 2024 | $2.03 | +125.6% |
| Dec 31, 2023 | $0.90 | +9.8% |
| Dec 31, 2022 | $0.82 | -18.8% |
| Dec 31, 2021 | $1.01 | +62.9% |
| Dec 31, 2020 | $0.62 | -43.1% |
| Dec 31, 2019 | $1.09 | -23.8% |
| Dec 31, 2018 | $1.43 | +180.4% |
| Dec 31, 2017 | $0.51 | N/A |
| Dec 31, 2016 | -$0.30 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,100 words across 20 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,138 | 20 | |
| 2026Q2 | Jun 30, 2026 | 6,868 | 19 | |
| 2026Q1 | Mar 31, 2026 | 7,126 | 18 | |
| 2025Q4 | Dec 31, 2025 | 8,548 | 23 | |
| 2025Q3 | Sep 30, 2025 | 7,746 | 19 | |
| 2025Q2 | Jun 30, 2025 | 8,198 | 23 | |
| 2025Q1 | Mar 31, 2025 | 8,591 | 22 | |
| 2024Q4 | Dec 31, 2024 | 6,022 | 20 |
2026Q3 Earnings Call
Opening remarks
Andrew Peters Senior Vice President of Strategy and Investor Relations Thank you, Towanda, and thank you all for joining us for the Exelixis Third Quarter 2026 Financial Results Conference Call. Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; Dana Aftab, our Executive Vice President of Research and Development; and P.J. Haley, our Executive Vice President of Commercial, who will review our progress for the third quarter of 2026, ended September 30, 2026. During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release, which is posted on our website, for an explanation of our reasons for using such non-GAAP measures, as well as tables deriving these measures from our GAAP results. During the course of the presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial and strategic matters, potential growth opportunities, and government drug pricing policies and initiatives. Actual events or results could, of course, differ materially. We refer you to the documents we file from time to time with the Securities and Exchange Commission, which, under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including, without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners, and the level of costs associated with discovery, product development, business development and commercialization activities. With that, I'll turn the call over to Mike.
Michael Morrissey President and CEO All right. Thank you, Andrew, and thanks to everyone for joining us on the call today. Exelixis had a strong third quarter and continues to advance the key components of our business. The company is well positioned to deliver on our strategic objectives and tactical goals for 2026 and beyond as we aspire to become a company with a diverse pipeline of potential oncology franchise assets and opportunities. Most importantly, zanzalintinib is positioned to drive the next phase of growth for Exelixis as our second franchise molecule, potentially first with the third-line-plus CRC opportunity, followed by several waves of pivotal trials that we'll highlight today. CABO's strong third quarter performance reinforces our confidence in its long-term revenue growth trajectory. We saw solid year-over-year growth in both the RCC and NET indications in Q3 and are excited about the potential of the CABO NET indication, which serves as the foundation of our future expanded NET franchise with zanza and other molecules in our pipeline.
Frequently Asked Questions About EXEL
When is Exelixis's next earnings date?
Exelixis's next earnings report is expected for Feb 8, 2027.
Did EXEL beat earnings estimates last quarter?
Yes. Exelixis reported EPS of $0.85 for the quarter ended Sep 30, 2026, above the $0.79 estimate, a 7.59% surprise.
What EPS do analysts expect from EXEL next quarter?
The consensus EPS estimate for Exelixis for the quarter ending Dec 31, 2026 is $1.00 from 19 analysts, with estimates from $0.77 to $1.23.
How often does EXEL beat earnings estimates?
Exelixis beat the EPS estimate in each of the last 10 quarters, with an average surprise of +29.96%.
EXEL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors